As AI bolsters the drug discovery pipeline, the boundaries of pharmaceuticals and technology are becoming increasingly blurred. Pharmaceutical giant Eli Lilly's unveiling earlier this year of its supercomputer LillyPod, developed in partnership with NVIDIA, epitomizes this evolution.
The Indianapolis-based AI factory LillyPod opened in February and is built with 1,016 of NVIDIA's high-powered Blackwell Ultra GPUs. It functions as a computational dry lab that works in tandem with Lilly's San Francisco-based agentic wet lab (where tangible drug development is happening) to speed up research and development.
